{"id":"W4281693510","doi":"10.1200/jco.2022.40.16_suppl.1018","title":"Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), <i>PIK3CA</i>-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia; BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Letrozole; Cohort; Internal medicine; Fulvestrant; Hazard ratio; Oncology; Breast cancer; Cancer; Gastroenterology; Estrogen receptor; Confidence interval; Aromatase","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.004858315,0.0005437459,0.002590957,0.0006018536,0.0002033395,0.0000263595,0.0005251757,0.0002059014,0.0003829128],"category_scores_gemma":[0.001045941,0.0003388647,0.0003927266,0.001555522,0.0004963838,0.0005347632,0.0001883351,0.001824863,6.008137e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007383055,"about_ca_system_score_gemma":0.0008302968,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007893699,"about_ca_topic_score_gemma":0.001305893,"domain_scores_codex":[0.9881776,0.005185165,0.003713986,0.0007347789,0.001659494,0.0005289975],"domain_scores_gemma":[0.9906393,0.003311329,0.004013048,0.0004790395,0.001257904,0.0002994023],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1145564,0.01760137,0.5907323,0.00001875124,0.002550803,0.0002413137,0.0030786,0.0001245507,0.009228573,0.00000437244,0.000210282,0.2616526],"study_design_scores_gemma":[0.07340799,0.0316245,0.8888697,0.0001199926,0.0003515235,0.00005174103,0.003014561,0.00005497303,0.001682608,0.0000444238,0.0004346764,0.0003432851],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9878187,0.001377529,0.00009664515,0.007264474,0.0003589359,0.002433274,0.0006064984,0.00001815413,0.00002578709],"genre_scores_gemma":[0.9943565,0.002415681,0.001280368,0.001184036,0.0002604986,0.0002736235,0.0001362692,0.00006962487,0.00002342229],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2981374,"threshold_uncertainty_score":0.9999064,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.031121113661463,"score_gpt":0.3935998460232075,"score_spread":0.3624787323617445,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}